ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

CRTX: Cornerstone Therapeutics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CORNERSTONE THERAPEUTICS INC (NASD)
CRTX	5.77	-0.18	(-3.03%)	Vol. 553,994	16:00 ET

CORNERSTONE THERAPEUTICS is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a deep late-stage clinical pipeline with six regulatory approval submissions expected between 2009 and 2010. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.

General Information

CORNERSTONE THR

60 Westview Street Lexington, MA 02421 Phone: 781-402-5700 Fax: 617-354-9318 Web: www.crtx.com Email: investor.relations@crtx.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/25/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	5.95
52 Week High	12.29
52 Week Low	1.72
Beta	-0.97
20 Day Moving Average	57,005.10
Target Price Consensus	13

% Price Change
4 Week	-6.94
12 Week	-22.13
YTD	117.74

% Price Change Relative to S&P 500
4 Week	-6.81
12 Week	-26.44
YTD	78.61

Share Information
Shares Outstanding (millions)	24.81
Market Capitalization (millions)	143.17
Short Ratio	2.69
Last Split Date	11/03/2008

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.00
Current Year EPS Consensus Estimate	0.39
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/25/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	14.79
Trailing 12 Months:	3.39
PEG Ratio	-

EPS Growth
vs. Previous Year	112.00%
vs. Previous Quarter	-53.85%

Sales Growth
vs. Previous Year	285.08%
vs. Previous Quarter:	-7.66%

Price Ratios
Price/Book	1.87
Price/Cash Flow	2.13
Price / Sales	1.44

ROE
09/30/09	35.80
06/30/09	35.60
03/31/09	10.05

ROA
09/30/09	16.42
06/30/09	14.97
03/31/09	3.51

Current Ratio
09/30/09	-
06/30/09	1.34
03/31/09	1.29

Quick Ratio
09/30/09	-
06/30/09	1.01
03/31/09	0.93

Operating Margin
09/30/09	12.47
06/30/09	11.21
03/31/09	2.72

Net Margin
09/30/09	-
06/30/09	48.63
03/31/09	49.63

Pre-Tax Margin
09/30/09	-
06/30/09	48.63
03/31/09	49.63

Book Value
09/30/09	-
06/30/09	3.09
03/31/09	2.88

Inventory Turnover
09/30/09	-
06/30/09	0.69
03/31/09	0.75

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.10
03/31/09	0.11


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research